Overview

• Reshma Kewalramani becomes the first woman to lead a major US biotechnology firm and debuts at number 62 on Fortune’s 2025 list of the 100 Most Powerful People in Business.
• Fortune’s profile credits her with steering Vertex to FDA approval for Journavx, an opioid-free pain medication.
• Kewalramani joined Vertex in 2017, was named chief medical officer in 2018 and has served as CEO and board member since April 2020.
• Born in Mumbai and raised in the United States from age 11, she leverages her physician training to drive Vertex’s research and development strategies.
• Her inclusion alongside leaders such as Sundar Pichai and Mukesh Ambani reflects increasing diversity at the top of global corporations.